Staphylococcus aureus sepsis in rheumatoid arthritis
- 11 March 2015
- journal article
- Published by Springer Nature in Rheumatology International
- Vol. 35 (9) , 1503-1510
Abstract
Patients with rheumatoid arthritis (RA) are at increased risk of infection. In this study, we determined the risk of and risk factors for Staphyococcus aureus (S. aureus) sepsis in RA. We assembled a retrospective nested case–control subset of RA patients with S. aureus sepsis from the Barnes-Jewish Hospital Medical Informatics database, confirmed the diagnoses, and collected data electronically and by chart review. We used multivariate logistic regression to identify independent risk factors for S. aureus sepsis, with risk expressed as odds ratios (ORs). We extracted data on the length of hospitalization and 30-day and 1-year mortality from the Medical Informatics database for all cases and controls. There were 48 confirmed S. aureus sepsis cases and 232 confirmed controls in the RA cohort. In multivariate analysis, indwelling central venous catheter (OR 15.97; 95 % CI 5.09–50.10; p < 0.01) and congestive heart failure (OR 2.89; 95 % CI 1.26–6.63; p = 0.01) were independently associated with risk of S. aureus sepsis, while treatment with disease-modifying anti-rheumatic drugs (DMARDs), both biologic and non-biologic, was not. S. aureus sepsis was associated with increased 30-day and 1-year mortality (OR 7.37; 95 % CI 2.86–19.0; p < 0.01 for 30-day and OR 5.24; 95 % CI 2.51–10.94; p < 0.01 for 1-year mortality) and longer hospitalization (p < 0.01). Treatment with biologic DMARDs was not associated with longer hospitalization (p = 0.89). Indwelling central venous catheters and congestive heart failure increased the risk of S. aureus sepsis in this observational cohort of patients with RA. Treatment with biologic and non-biologic DMARDs did not increase this risk.Keywords
This publication has 27 references indexed in Scilit:
- Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort studyBMC Infectious Diseases, 2014
- Bacteremia in patients receiving TNF-alpha antagonists – A prospective multicenter studyJournal of Infection, 2013
- Excess Mortality and Long-Term Disability from Healthcare-Associated Staphylococcus aureus Infections: A Population-Based Matched Cohort StudyPLOS ONE, 2013
- Persistent Catheter-Related Staphylococcus aureus Bacteremia after Catheter Removal and Initiation of Antimicrobial TherapyPLOS ONE, 2012
- Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemiaClinical Microbiology and Infection, 2012
- TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid ArthritisMedicine, 2011
- The risk of infection associated with tumor necrosis factor α antagonists: Making sense of epidemiologic evidenceArthritis & Rheumatism, 2008
- The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western SwedenScandinavian Journal of Infectious Diseases, 2007
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006